Dure geneesmiddelen * (extramuraal), de vergoeding in 2019
- Raming voor de totale Zvw-populatie
| 2015 | 2016 | 2017 | 2018 | 2019 | ||
|---|---|---|---|---|---|---|
| Rang 2019 |
ATC-code | |||||
| 1 | R07AX30 Ivacaftor met lumacaftor (Orkambi ®) | . | . | 5.765.200 | 89.977.700 | 67.618.300 |
| 2 | J06BA02 Immunoglobuline normaal intravasculair (Nanogam ®) | 41.989.900 | 48.124.700 | 53.707.300 | 61.820.000 | 67.284.900 |
| 3 | N04BA02 Levodopa met decarboxylaseremmer (Sinemet ®) | 28.568.100 | 31.931.800 | 35.995.500 | 38.667.400 | 43.312.700 |
| 4 | C10AX13 Evolocumab (Repatha ®) | . | 5.752.200 | 20.209.900 | 33.380.700 | 39.972.700 |
| 5 | L04AX07 Dimethylfumaraat (Tecfidera ®) | 16.075.200 | 20.508.000 | 23.228.100 | 32.246.400 | 38.396.100 |
| 6 | L04AD02 Tacrolimus (Prograft ®) | 26.778.400 | 28.406.600 | 29.575.200 | 31.590.300 | 33.159.100 |
| 7 | J05AR13 Lamivudine met abacavir en dolutegravir (Triumeq ®) | 16.215.800 | 28.113.000 | 32.077.600 | 35.228.800 | 32.832.500 |
| 8 | J05AR18 Emtricitabine tenofovir alafenamide elvitegravir cobicista (Genvoya ®) | . | 8.899.200 | 26.089.100 | 33.745.400 | 31.901.400 |
| 9 | C10AX14 Alirocumab (Praluent ®) | . | 1.933.100 | 9.789.700 | 20.152.500 | 30.215.700 |
| 10 | B03XA02 Darbepoetine alfa (Aranesp ®) | 24.510.900 | 24.146.400 | 24.134.500 | 25.993.000 | 28.491.300 |
| 11 | L04AA27 Fingolimod (Gilenya ®) | 21.522.300 | 22.922.700 | 24.383.400 | 27.139.200 | 27.436.800 |
| 12 | H01CB03 Lanreotide (Somatuline ®) | 15.102.000 | 16.764.400 | 18.777.100 | 20.823.000 | 23.329.200 |
| 13 | H01CB02 Octreotide (Sandostatine ®) | 24.552.000 | 24.451.100 | 23.381.300 | 23.425.700 | 22.691.300 |
| 14 | R07AX02 Ivacaftor (Kalydeco ®) | 4.888.100 | 9.158.500 | 9.043.200 | 10.484.000 | 22.191.700 |
| 15 | A09AA02 Multi-enzymen (lipase protease enz) (Creon ®) | 15.975.500 | 16.826.000 | 17.931.600 | 18.893.500 | 21.080.200 |
| 16 | C02KX04 Macitentan (Opsumit ®) | 7.469.900 | 12.536.400 | 15.309.000 | 18.914.600 | 20.294.500 |
| 17 | J05AR20 Emtricitabine met tenofoviralafenamide en bictegravir (Biktarvy ®) | . | . | . | 865.390 | 15.874.400 |
| 18 | J05AX12 Dolutegravir (Tivicay ®) | 6.356.400 | 10.339.000 | 12.187.500 | 14.405.900 | 15.837.200 |
| 19 | L02AE02 Leuproreline (Lucrin pds ®) | 14.299.900 | 14.602.400 | 15.245.300 | 15.711.000 | 15.811.800 |
| 20 | L03AA13 Pegfilgrastim (Neulasta ®) | 23.793.500 | 17.683.500 | 14.646.000 | 15.901.900 | 15.459.700 |
| Totaal | 288.097.900 | 343.099.000 | 411.476.500 | 569.366.390 | 613.191.500 | |